| Results of a study investigating zanubrutinib combined with obinutuzumab and venetoclax for treatment of CLL. |
Home / Resource Library / MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial